Adage Capital Partners Gp, L.L.C. Gilead Sciences, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,714,130 shares of GILD stock, worth $191 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
1,714,130Holding current value
$191 Million% of portfolio
0.29%Shares
26 transactions
Others Institutions Holding GILD
# of Institutions
2,101Shares Held
1.02BCall Options Held
8.73MPut Options Held
9.63M-
Black Rock Inc. New York, NY121MShares$13.4 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$12.9 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA71.7MShares$7.99 Billion1.05% of portfolio
-
State Street Corp Boston, MA60.4MShares$6.73 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA57.9MShares$6.46 Billion1.15% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $140B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...